Strong growth anticipation may have inflated P/E ratio yet inconsistent recent earnings cast doubt on its sustainability. Current stock prices may not be sustainable as recent trends could affect share price.
A rise in insider selling at Aehr Test Systems signals caution for shareholders. Despite its profitability and growth, the low level of insider ownership raises concerns. Current insider trends suggest it might not be an ideal investment choice.
Pre-Market Stock Movers Gapping up $先锋自然资源(PXD.US)$soared nearly 10% in premarket trading after The Wall Street Journal reported Pioneer was close to reaching a deal to be bought by Exxon Mobil for about $60 billion. Shares of Exxon were down 3%. $Apellis Pharmaceuticals(APLS.US)$Shares rose 5.5% after Apellis reported growing sales for its Syfovre drug in August. JPMorgan upgraded the stock to ov...
Summary: 1. Aehr Test Systems reported record financial performance in Q4 and fiscal year 2023 with revenue increasing by 28% YoY to $65 million. 2. The company generated a record $10 million in operating cash flow in fiscal 2023, up more than 500% from the prior year, and expects full year total revenue to be at least $100 million in fiscal 2024, representing growth of over 50% YoY. 3. Aehr's strong financial position includes a c...
Aehr Test Systems股票讨论区
$AEHR Support / Resistance Levels
Larger Image: tradingview.com...
$Aehr Test Systems(AEHR.US)$
1997年上市,主要做测试系统业务,主要市场在亚洲,当前价格17.88。
5年来营收前3年萎缩,2022年大幅增长2倍,2023年继续增长27.8%,营业利润2022年扭亏,2023年增长71%,净利润2023年增长54%,
2024上半年营收增长65%,营业利润增长1.4倍,净利润增长1.5倍。
应收和存货的比例和增速都略快,存货占2023年营收的37%,应收占25.5%。
5年来现金流经营净额低于投资净额,还未产生股东盈余。
目前市盈率36.3,市盈率TTM25.6,可以多观察几个季度再判断。
🚀🚀🚀🚀🚀🚀
📊⚡️📊
专栏Today's Pre-Market Stock Movers and Top Ratings: TSLA, LEVI, PXD, APLS and More
Gapping up
$先锋自然资源(PXD.US)$ soared nearly 10% in premarket trading after The Wall Street Journal reported Pioneer was close to reaching a deal to be bought by Exxon Mobil for about $60 billion. Shares of Exxon were down 3%.
$Apellis Pharmaceuticals(APLS.US)$ Shares rose 5.5% after Apellis reported growing sales for its Syfovre drug in August. JPMorgan upgraded the stock to ov...
专栏Aehr Test Systems (AEHR) Q4 2023 Earnings Call Transcript Summary
1. Aehr Test Systems reported record financial performance in Q4 and fiscal year 2023 with revenue increasing by 28% YoY to $65 million.
2. The company generated a record $10 million in operating cash flow in fiscal 2023, up more than 500% from the prior year, and expects full year total revenue to be at least $100 million in fiscal 2024, representing growth of over 50% YoY.
3. Aehr's strong financial position includes a c...
暂无评论